Neda Saraygord-Afshari

Dr. Neda Saraygord-Afshari

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Journal of Chromatography A
Verified
Journal Article
Closed access
PLPey Yee Lee
Pey Yee Lee
NSNeda Saraygord-Afshari
Neda Saraygord-Afshari
TLTeck Yew Low
Teck Yew Low

2 April 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MPMohammad Panahi
Mohammad Panahi
BRBahareh Rahimi
Bahareh Rahimi
GRGolbarg Rahimi
Golbarg Rahimi
TLTeck Yew Low
Teck Yew Low
NSNeda Saraygord-Afshari
Neda Saraygord-Afshari
EAEffat Alizadeh
Effat Alizadeh

25 April 2023 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
BRBahareh Rahimi
Bahareh Rahimi
MPMohammad Panahi
Mohammad Panahi
HLHajie Lotfi
Hajie Lotfi
MKMostafa Khalili
Mostafa Khalili
ASAstireh Salehi
Astireh Salehi
EAEffat Alizadeh
Effat Alizadeh
Background: The physiological level of reactive oxygen species (ROS) is necessary for many cellular functions. However, during the in-vitro manipulations, cells face a high level of ROS, leading to reduced cell quality. Preventing this abnormal ROS level is a challenging task. Hence, here we evaluated the effect of sodium selenite supplementation on the antioxidant potential, stemness capacity, and differentiation of rat-derived Bone Marrow MSCs (rBM-MSCs) and planned to check our hypothesis on the molecular pathways and networks linked to sodium selenite’s antioxidant properties. Methods: MTT assay was used to assess the rBM-MSCs cells’ viability following sodium selenite supplementation (concentrations of: 0.001, 0.01, 0.1, 1, 10 µM). The expression level of OCT-4, NANOG, and SIRT1 was explored using qPCR. The adipocyte differentiation capacity of MSCs was checked after Sodium Selenite treatment. The DCFH-DA assay was used to determine intracellular ROS levels. Sodium selenite-related expression of HIF-1α, GPX, SOD, TrxR, p-AKT, Nrf2, and p38 markers was determined using western blot. Significant findings were investigated by the String tool to picture the probable molecular network. Results: Media supplemented with 0.1 µM sodium selenite helped to preserve rBM-MSCs multipotency and keep their surface markers presentation; this also reduced the ROS level and improved the rBM-MSCs’ antioxidant and stemness capacity. We observed enhanced viability and reduced senescence for rBM-MSCs. Moreover, sodium selenite helped in rBM-MSCs cytoprotection by regulating the expression of HIF-1 of AKT, Nrf2, SOD, GPX, and TrxR markers. Conclusions: We showed that sodium selenite could help protect MSCs during in-vitro manipulations, probably via the Nrf2 pathway.

2 December 2014 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
NSNeda Saraygord-Afshari
Neda Saraygord-Afshari
HNHossein Naderi-Manesh
Hossein Naderi-Manesh
MNMostafa Naderi
Mostafa Naderi

21 January 2015 in International Journal of Proteomics
Verified
Journal Article
Open access
PDF file
ZPZaiddodine Pashandi
Zaiddodine Pashandi
NSNeda Saraygord-Afshari
Neda Saraygord-Afshari
HNHossein Naderi-Manesh
Hossein Naderi-Manesh
MNMostafa Naderi
Mostafa Naderi
Objective.Sulfur mustard (SM) is a highly reactive alkylating agent which produces ocular, respiratory, and skin damages. Eyes are the most sensitive organ to SM due to high intrinsic metabolic and rapid turnover rate of corneal epithelium and aqueous-mucous interfaces of the cornea and conjunctiva. Here we investigate underlying molecular mechanism of SM exposure delayed effects which is still a controversial issue after about 30 years.Materials and Methods.Following ethical approval, we have analyzed serum proteome of ten severe SM exposed male patients with delayed eye symptoms with two-dimensional electrophoresis followed by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight mass spectrometry. The western blotting was used to confirm the proteins that have been identified.Results.We have identified thirteen proteins including albumin, haptoglobin, and keratin isoforms as well as immunoglobulin kappa chain which showed upregulation while transferrin and alpha 1 antitrypsin revealed downregulation in these patients in comparison with healthy control group.Conclusions.Our results elevated participation of free iron circulatory imbalance and local matrix-metalloproteinase activity in development of delayed ocular symptoms induced by SM. It demonstrates that SM induced systemic toxicity leads to some serum protein changes that continually and gradually exacerbate the ocular surface injuries.

22 August 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
NRNegar Etehad Roudi
Negar Etehad Roudi
NSNeda Saraygord-Afshari
Neda Saraygord-Afshari
MHMaryam Hemmaty
Maryam Hemmaty
Since 1980, when the idea of drug-delivery was proposed, various drug-carriers have been developed, including DNA, proteins, liposomes and several other polymer cages, consisting of many well established natural and synthetic nano-particles. All these drug-carriers can self-assemble in the body and can be manipulated for safer delivery into target tissues. By definition, nano-scale drug delivery systems encompass any structure (either cage or particle) in the form of solid colloids, which range in size from 10 nm to 100 nm. Today, optimization of these nano drug-vehicles is a topic in many research centers. Researchers are trying to improve the carrier’s solubility and their loading capacity and also wish to increase the half-life of drug delivery cargos in target tissues. Efforts in recent years have led to the introduction of novel protein nano-cages composed of multiple protein subunits, which self-assemble within a superfine and precise format. Science their introduction these promising structure have shown many unique characteristics, including low toxicity, bio-system compatibility, minor immunogenicity, high solubility, and a relatively easy production in large scale. Herein, we review and discuss the recently developed protein nano-carriers that are used as drug cargos for targeted delivery and/or diagnostic tools.